CAMBRIDGE, Mass., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will participate in the Jefferies Global Healthcare Conference in London, England. Mark Fitzpatrick, CFO of Aegerion, is scheduled to present on Thursday, November 15, 2012 at 1:40 pm GMT.
Aegerion Pharmaceuticals is an emerging biopharmaceutical company focused on the development and commercialization of novel, life-altering therapeutics to treat debilitating and often fatal rare diseases. The company's lead drug candidate, lomitapide, is in late-stage development for the treatment of homozygous familial hypercholesterolemia (HoFH), a rare life-threatening disease characterized by severely elevated cholesterol levels.
Aegerion is motivated by its commitment to patients first, as well as its core values of integrity, innovation, responsibility to healthcare providers and development of employees, with a constant focus on scientific and clinical excellence. For more information, visit www.aegerion.com.
CONTACT: Aegerion Pharmaceuticals, Inc. Michael Lawless, VP, IR 857-242-5028Source:Aegerion Pharmaceuticals, Inc.